Impact of Respiratory Bacterial Findings on Patients with Chronic Pulmonary Aspergillosis
Table 1
Baseline characteristics of study participants (N = 142).
Total (N = 142)
Age (years)
67 (60–74)
Sex (male)
94 (66.2)
Body mass index (kg/m2)
19.6 (17.3–22.4)
Underlying lung disease†
Previous history of pulmonary tuberculosis
97 (68.3)
Nontuberculous mycobacterial pulmonary disease
48 (33.8)
Bronchiectasis
46 (32.4)
Emphysema
45 (31.7)
Interstitial lung disease
9 (6.3)
Previous history of thoracic malignancy
8 (5.6)
Other comorbidities†
Diabetes mellitus
35 (24.6)
Congestive heart disease
11 (7.7)
Chronic hepatic insufficiency
9 (6.3)
Chronic renal insufficiency
7 (4.9)
Rheumatic disease
9 (6.3)
Previous history of extrathoracic malignancy
9 (6.3)
Chronic pulmonary symptoms†
Cough
62 (43.7)
Sputum
74 (52.1)
Breathlessness‡
57 (40.1)
Hemoptysis
57 (40.1)
Chest computed tomographic findings†
Cavitation
142 (100)
Paracavitary infiltrates
133 (93.7)
Mycetoma
41 (28.9)
Consolidation
12 (8.5)
Bilateral pulmonary lesions
37 (26.1)
Laboratory findings
White blood cells (μL)
7,955 (6,018−9,913)
C-reactive protein (mg/L)
11.0 (2.3–34.0)
Albumin (g/dL)
4.1 (3.6–4.4)
Microbiological tests
Positive serum Aspergillus precipitin antibody test
142 (100)
Aspergillus culture
7 (4.9)
Data are presented as the median (interquartile range) or number (%). †Cases are duplicated. ‡Breathlessness represents a modified Medical Research Council dyspnea score ≥ 2.
